NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 76 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q3 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,604,294 | -18.3% | 1,457,055 | 0.0% | 0.11% | -40.7% |
Q2 2023 | $5,638,803 | +39.7% | 1,457,055 | 0.0% | 0.18% | +26.4% |
Q1 2023 | $4,036,042 | +153771.2% | 1,457,055 | 0.0% | 0.14% | +82.3% |
Q4 2022 | $2,623 | -99.9% | 1,457,055 | 0.0% | 0.08% | +43.6% |
Q3 2022 | $3,089,000 | -21.2% | 1,457,055 | 0.0% | 0.06% | -36.0% |
Q2 2022 | $3,919,000 | -38.0% | 1,457,055 | 0.0% | 0.09% | +16.2% |
Q1 2022 | $6,324,000 | -16.2% | 1,457,055 | 0.0% | 0.07% | +68.2% |
Q4 2021 | $7,548,000 | -15.6% | 1,457,055 | 0.0% | 0.04% | -97.6% |
Q3 2021 | $8,946,000 | -39.2% | 1,457,055 | 0.0% | 1.82% | -52.6% |
Q2 2021 | $14,716,000 | – | 1,457,055 | – | 3.85% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
AH Equity Partners Bio II, L.L.C. | 16,298,006 | $16,298,000 | 8.49% |
Madrona Venture Group, LLC | 6,020,770 | $31,188,000 | 5.89% |
ArchPoint Investors | 1,449,551 | $7,509,000 | 2.23% |
Ally Bridge Group (NY) LLC | 1,225,060 | $6,346,000 | 2.22% |
Affinity Asset Advisors, LLC | 1,049,721 | $5,438,000 | 1.98% |
Tikvah Management LLC | 1,231,835 | $6,381,000 | 1.78% |
Bain Capital Life Sciences Investors, LLC | 2,000,000 | $10,360,000 | 0.82% |
AH Equity Partners LSV II, L.L.C. | 1,355,911 | $1,356,000 | 0.74% |
Perceptive Advisors | 18,222,302 | $94,390,000 | 0.73% |
SPHERA FUNDS MANAGEMENT LTD. | 800,000 | $4,144,000 | 0.46% |